Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials

Cancer Treatment Reviews

Volumn 40, Issue 5, 2014, Pages 675-683

  Del Mastro, Lucia ^a   Ceppi, Marcello ^a   Poggio, Francesca ^a   Bighin, Claudia ^a   Peccatori, Fedro ^b   Demeestere, Isabelle ^c   Levaggi, Alessia ^a   Giraudi, Sara ^a   Lambertini, Matteo ^a   D'Alonzo, Alessia ^a   Canavese, Giuseppe ^a   Pronzato, Paolo ^a   Bruzzi, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Breast cancer; Chemotherapy induced ovarian failure; Fertility preservation; GnRH analogues; Lymphoma; Meta analysis

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CHEMOTHERAPY INDUCED PREMATURE OVARIAN FAILURE; DRUG EFFICACY; HUMAN; LYMPHOMA; META ANALYSIS; NEOPLASM; OVARY CANCER; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

BREAST CANCER; CHEMOTHERAPY-INDUCED OVARIAN FAILURE; FERTILITY PRESERVATION; GNRH ANALOGUES; LYMPHOMA; META-ANALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GONADOTROPIN-RELEASING HORMONE; HODGKIN DISEASE; HUMANS; PATIENT SAFETY; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898469312     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.12.001     Document Type: Review

References (42)

1. Partridge A., Gelber S., Gelber R.D., Castiglione-Gertsch M., Goldhirsch A., Winer E. Age at menopause among women who remain premenopausal following treatment for early breast cancer. Long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007, 43(11):1646-1653.
2. Schover L.R. Premature ovarian failure and its consequences vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008, 26(5):753-758.
3. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist 2007, 12(9):1044-1054.
4. Ataya K., Rao L.V., Lawrence E., Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995, 52(2):365-372.
5. Del Mastro L., Catzeddu T., Boni L., et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Ann Oncol 2006, 17(1):1774-1778.
6. Urruticoechea A., Amedos M., Waslsh G., Dowsett M., Smith I.E. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer. Breast Cancer Res Treat 2008, 110(3):411-416.
7. Recchia F., Saggio G., Amiconi G., et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006, 106(3):514-523.
8. Blumenfeld Z., von Wolff M. GnRH analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008, 14(6):543-552.
9. Clowse M.E., Behera M.A., Anders C.K., et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009, 18(3):311-319.
10. Ben-Aharon I., Gafter-Gvili A., Leibovici L., Stemmers S.M. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010, 122(3):803-811.
11. Kim S.S., Lee J.R., Jee B.C., et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010, 53(4):740-752.
12. Bedaiwy M.A., Abou-Setta A.M., Desai N., et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011, 95(3):906-914.
13. Chen H., Li J., Cui T., Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011, 11. 10.1002/14651858.CD008018.pub2.
14. Yang B., Shi W., Yang J., et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast 2013, 22(2):150-157.
15. Wang C., Chen M., Fu F., Huang M. Gonadotropin releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS ONE 2013, 8e66360.
16. Turner N.H., Partridge A., Sanna G., Di Leo A., Biganzoli L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients the benefit remains uncertain. Ann Oncol 2013, 24(9):2224-2235.
17. Gilani M.M., Hasanzadeh M., Ghaemmaghami F., Ramazanzadeh F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia-Pac J Clin Oncol 2007, 3(2):79-83.
18. Badawy A., Elnashar A., El-Ashry M., Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91(3):694-697.
19. Sverrisdottir A., Nystedt M., Johansson H., Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer results from a randomized trial. Breast Cancer Res Treat 2009, 117(3):561-567.
20. Behringer K., Wildt L., Mueller H., et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010, 21(10):2052-2060.
21. Del Mastro L., Boni L., Michelotti A., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011, 306(3):269-276.
22. Gerber B., von Minckwitz G., Stehle H., et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011, 29(17):2334-2341.
23. Munster P.N., Moore A.P., Ismail-Khan R., et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012, 30(5):533-538.
24. Demeestere I., Brice P., Peccatori F.A., et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013, 31(7):903-909.
25. Elgindy E.A., El-Haieg D.O., Khorshid O.M., et al. Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013, 121(1):78-86.
26. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
27. Higgins J., Thompson S., Deeks J., Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002, 7(1):51-61.
28. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
29. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
30. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
31. Harbord R.M., Egger M., Sterne J.A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006, 25(20):3443-3457.
32. Stata Statistical Software Release 11 College Station 2009, Stata Corp. LP, TX.
33. Giuseppe L., Attilio G., Edoardo D.N., Loredana G., Cristina L., Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007, 12(2):141-147.
34. Leonard R.C., Adamson D., Anderson R., et al. The option trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010, 28(15):590.
35. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3, <>; 2013. http://www.nccn.org.
36. Loren A.W., Mangu P.B., Beck L.N., et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(19):2500-2510.
37. Peccatori F.A., Azim H.A., Orecchia R. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(6):160-170.
38. Waxman J.H., Ahmed R., Smith D., et al. Failure to preserve fertility in patients with Hodgkins disease. Cancer Chemother Pharmacol 1987, 19(2):159-162.
39. Fletcher J. What is heterogeneity and is it important?. BMJ 2007, 334(7584):94-96.
40. Lee S., Kil W.J., Chun M., et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 2009, 16(1):98-103.
41. Demeestere, I., Brice, P., Peccatori, F.A. et al., Triptorelin to prevent chemotherapy-induced ovarian failure in lymphoma patients: a prospective randomized study. The 3rd world congress of the international society for fertility preservation (ISFP). Valencia, November 7-9, 2013.
42. Behringer K., Thielen I., Mueller H., et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012, 23(7):1818-1825.